We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.
- Authors
Wang, Wen-Ting; Zhu, Hua-Yuan; Wu, Yu-Jie; Xia, Yi; Wu, Jia-Zhu; Wu, Wei; Liang, Jin-Hua; Wang, Li; Fan, Lei; Li, Jian-Yong; Xu, Wei
- Abstract
Purpose: The aim of this study was to investigate the prognostic significance of the absolute natural killer (NK) cell counts in peripheral blood in patients with chronic lymphocytic leukemia (CLL). Methods: A total of 273 previously untreated patients with CLL from April 2004 and October 2015 were enrolled into this retrospective study. We analysed the T cell subsets of all patients and figured out the number of NK cells. Comparisons of NK cell count as continuous parameter in different groups were described using Mann–Whitney U test and the Kruskal–Wallis test. Kaplan–Meier method was used to survival analysis, and the Cox proportional hazards models were used for the estimation of prognostic factors.Results: NK cell counts were calculated in 273 therapy-naive CLL patients, and higher number of NK cell was observed in those with Binet stage A/B, ZAP-70 < 20%, normal serum albumin and β2-microglobulin levels. Using a NK cell count cut-off of 0.40 × 109/L, patients with lower NK cell count (< 0.40 × 109/L) had a significantly shorter overall survival (OS) than those with higher NK cell count (≥ 0.40 × 109/L) (<italic>P</italic> = 0.0014). Multivariate analysis showed that NK cell counts remained its prognostic value. However, the effect of NK cell count on time to treatment was not significant. Conclusions: Our results suggest that NK cell count is an independent prognostic marker for OS in patients with CLL and NK cell counts ≥ 0.40 × 109/L can routinely be used to identify patients with favorable survival.
- Subjects
KILLER cells; CHRONIC lymphocytic leukemia treatment; T cells; PROPORTIONAL hazards models; LEUKEMIA; PROGNOSIS
- Publication
Journal of Cancer Research & Clinical Oncology, 2018, Vol 144, Issue 3, p449
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-017-2568-2